Belumosudil mesylate is a Small Molecule owned by Kadmon Holdings, and is involved in 29 clinical trials, of which 17 were completed, 6 are ongoing, and 6 are planned.
KD-025 is a ROCK2 (Rho-associated coiled-coiled kinase 2) inhibitor. ROCK2 inhibition with KD025 down-regulates the secretion of IL-21 and IL-17, two pro-inflammatory cytokines involved in the pathology of many autoimmune diseases, and concurrently up-regulates the suppressive function of regulatory T cells (Treg), helping to resolve inflammation, with a minimal effect on the rest of the immune response. ROCK2 inhibition down-regulates STAT3 and increases STAT5 which leads to resolve inflammation with a minimal effect on the rest of the immune response.
The revenue for Belumosudil mesylate is expected to reach a total of $6.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Belumosudil mesylate NPV Report.
Belumosudil mesylate Overview
Belumosudil mesylate (Rezurock/ Rholistiq) is an immunosuppressant. It is formulated as film coated tablets and tablets for oral route of administration. Rezurock is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy and who have an inadequate response to corticosteroids. Belumosudil mesylate (KD-025, SLx-2119) is under development for the treatment of idiopathic pulmonary fibrosis, diffuse cutaneous systemic sclerosis and graft versus host disease. It is a small molecule administered through orally and parenteral route. It is a selective inhibitor of Rho kinase 2 (ROCK2). It is developed based on Pharmacomer Technology Platform. It was also under development for the treatment of atherosclerosis, Sjogren’s syndrome, NASH (Nonalcoholic steatohepatitis), inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, psoriatic arthritis, systemic sclerosis (scleroderma), psoriasis vulgaris, rheumatoid arthritis and lupus nephritis.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.
Quick View – Belumosudil mesylate
|Highest Development Stage|